The authors alone are responsible for the views expressed in this article, and they do not necessarily represent the decisions, policy or views of the institutions which with they are affiliated. DMK is a consultant to Sanofi Pasteur and coinventor of a patent covering the use of replication-defective mutants as herpes simplex vaccines, which has been licensed by Harvard University to Sanofi Pasteur. LC reports holding stock
in Immune Design, and is a co-inventor on several patents associated with identifying T-cell antigens to HSV-2 that are directed at an HSV-2 vaccine. J.I.C. has a Cooperative Research and Development Agreement (CRADA) with Sanofi Pasteur that provides funding to evaluate an HSV-2 vaccine in a clinical trial, and
a CRADA with Immune Design Corporation that provided funding to test a therapeutic HSV-2 vaccine in an animal model. CDD reports no conflicts of interest. “
“Tubal factor infertility (TFI) is a globally significant public selleck products health problem caused by several microbial agents, including untreated genital infections with Chlamydia trachomatis [1]. C. trachomatis remains the most commonly reported infectious disease in many countries. It is estimated that in 2008, there were 106 million new cases of C. trachomatis in adults (15–49 years) with an estimated 100 million people infected at any one time [2]. These acute infections translate into significant downstream health costs with an estimated 714,000 disability-adjusted life
years (DALYs) lost as a result of C. trachomatis infections [3]. In the United States alone, direct medical costs for chlamydial infections exceed US$ 500 million Navitoclax annually, excluding costs for screening programmes and indirect costs like lost productivity [4]. The largest burden of disease from C. trachomatis is in women where untreated genital infections can lead to pelvic inflammatory disease (PID) and, in some cases, sequelae including TFI (18% cases following symptomatic PID) resulting from fallopian tube scarring [1] and [5]. Infections during pregnancy may cause premature labour and may also cause neonates to develop conjunctivitis or pneumonia [6]. The high prevalence the of infections among women of child-bearing age exposes an estimated 100,000 neonates to Chlamydia annually in the United States [7]. In men, C. trachomatis is the most commonly reported sexually transmitted infection (STI) and the leading cause of non-gonococcal (non-specific) urethritis [8] and [9]. Following upper genital tract ascension, C. trachomatis may cause acute infectious epididymitis [10]; C. trachomatis infections have been reported in 40–85% men with epididymitis [11]. However, up to 90% of chlamydial infections in females and 50% in males are asymptomatic. This indicates that the incidence of reported chlamydial infections from surveillance data is likely a gross global under-estimate and that screening of asymptomatics would detect even more infections [12], [13] and [14].